[Print-Friendly Table (PDF)]

[Errata: Palivizumab Doses]

Table 3.61. Maximum Number of Palivizumab Doses for RSV Prophylaxis of Preterm Infants Without Chronic Lung Disease, on the Basis of Birth Date, Gestational Age, and Presence of Risk Factors (Shown for Geographic Areas Beginning Prophylaxis on November 1)^a

Maximum No. of Doses for Season Beginning November 1 Month of Birth 28 Weeks, 6 Days of Gestation and <12 Months of Age at Start of Season 29 Weeks, 0 Days Through 31 Weeks, 6 Days of Gestation and <6 Months of Age at Start of Season 32 Weeks, 0 Days Through 34 Weeks, 6 Days of Gestation and With Risk Factorb November 1–March 31 of previous RSV season 5c 0d 0e April 5 0d 0e May 5 5 0e June 5 5 0e July 5 5 0e August 5 5 1f September 5 5 2f October 5 5 3f November 5 5 3f December 4 4 3f January 3 3 3f February 2 2 2f March 1 1 1f aIf infant is discharged from the hospital during RSV season, fewer doses may be required. bFor risk factors, see p 565–566. cSome of these infants may have received 1 or more doses of palivizimab in the previous RSV season if discharged from the hospital during that season; if so, they still qualify for up to 5 doses during their second RSV season. dZero doses because infant will be older than 6 months of age at start of RSV season. eZero doses because infant will be older than 90 days of age at start of RSV season. fOn the basis of the age of patients at the time of discharge from the hospital, fewer doses may be required, because these infants will receive 1 dose every 30 days until the infant is 90 days of age.